Abstract:Baogen Zhang, 1, &ast Biqing Huang, 2, &ast Fan Yang, 3, &ast Jiandong Yang, 1 Man Kong, 1 Jing Wang, 1 Yaoxian Xiang, 1 Kangjie Wang, 1 Ruchen Peng, 4 Kun Yang, 4 Chao An, 5 Dong Yan 1 1 Department of Oncology, Beijing Luhe Hospital Affiliated to Capital Medical University, Beijing, 101149, People's Republic of China; 2 Department of Interventional Radiology and Vascular Surgery, The First Affiliated Hospital of Jinan University, Guangzhou, 510630, People's Republic of China; 3 Department of Cardiology, The First Affiliated Hospital of Jinan University, Guangzhou, 510630, People's Republic of China; 4 Department of Medical Imaging, Beijing Luhe Hospital Affiliated to Capital Medical University, Beijing, 101149, People's Republic of China; 5 Department of Minimal Invasive Intervention, Sun Yat-sen University Cancer Center; State Key Laboratory of Oncology in South China; Collaborative, Innovation Center for Cancer Medicine, Guangzhou, 510060, People's Republic of China &astThese authors contributed equally to this work Correspondence: Dong Yan, Department of Oncology, Beijing Luhe Hospital Affiliated to Capital Medical University, Beijing, 101149, People's Republic of China, Tel/Fax +86-10-69543901, Email Chao An, Department of Minimal invasive intervention, Sun Yat-sen University Cancer Center; State Key Laboratory of Oncology in South China; Collaborative, Innovation Center for Cancer Medicine, Guangzhou, 510060, People's Republic of China, Tel/Fax +86-20-87343272, Email Objective: To compare the efficacy and safety of hepatic arterial infusion chemotherapy (HAIC) with transarterial chemoembolization (TACE) for the treatment of high-risk hepatocellular carcinoma (hHCC) patients. Methods: Between January 2014 and August 2022, a total of 1765 consecutive patients with hHCC who underwent initial intra-arterial therapies were reviewed and divided into a TACE group (n, 507) and a HAIC group (n, 426). The study used propensity score matching (PSM) to reduce selectivity bias. Overall survival (OS) and progression-free survival (PFS) were compared using Kaplan‒Meier curves with the Log rank test. The objective response rate (ORR), conversion surgery rate (CSR) adverse event (AE) comparison and subgroup analysis were performed between the two groups. Results: After PSM 1:1, 444 patients were divided into two groups. The patients with hHCC who received HAIC had higher median PFS (6.1 vs 3.3 months, P < 0.001) and OS (10.3 vs 8.2 months, P =0.303) than TACE. Higher ORR (24.8% vs 11.7%) and CSR (15.5% vs 8.9%) were found in the HAIC group than in the TACE group (both P < 0.05). The incidence of grade 3/4 AE was 23.9% and 8.1% in the TACE and HAIC groups, respectively. The subgroup analysis suggest that HAIC appeared to particularly benefit patients with tumor diameter of more than 10 centimeters (hazard ratio [HR], 0.6; 95% CI, 0.47– 0.77; p, 0.00) and PVTT Vp4 (HR, 0.56; 95% CI, 0.39– 0.8; P , 0.01) for PFS outperforming TACE. Conclusion: HAIC can provide better disease control for hHCC than cTACE, with a comparable long-term OS and safety. Keywords: hepatocellular carcinoma, transarterial chemoembolization, hepatic artery infusion chemotherapy, high risk Hepatocellular carcinoma (HCC) is the sixth most common cancer and the third leading cause of cancer-related mortality worldwide, 1 and a large proportion of patients are in advanced stages at the time of diagnosis, with a poor prognosis, especially for patients with the combination of portal vein tumor thrombosis (PVTT), 2–4 bile duct invasion or large HCC with high tumor burden. 5 Previously, the IMbrave150 study defined combined Vp4 portal vein embolization, bile duct invasion, and tumor infiltration volume of more than 50% as high risk, 6 but significant challenges remain in the treatment of these populations. Transarterial chemoembolization (TACE) is recommended for the treatment of advanced HCC according to the National Comprehensive Cancer Network (NCCN) and China Liver Cancer Staging (CNLC) guidelines, including the BRIDGE study, which showed that TACE is a commonly used therapy for the treatment of advanced HCC. 7 However, the Barcelona Clinic Liver Cancer (BCLC) staged treatment algorithm endorsed by the American Association for the Study of Liver Diseases (ASLD) and the European Association for the Study of the Liver (EASL) do not recommend TACE for patients with PVTT. 5,8 VP4 in particular remains a relative contraindication to TACE due to the pot -Abstract Truncated-

Arterial chemotherapy for hepatocellular carcinoma in China: consensus recommendations

Revisiting Hepatic Artery Infusion Chemotherapy in the Treatment of Advanced Hepatocellular Carcinoma

Consensus of Minimally Invasive and Multidisciplinary Comprehensive Treatment for Hepatocellular Carcinoma – 2020 Guangzhou Recommendations

Hepatic Arterial Infusion Chemotherapy is a Feasible Treatment Option for Hepatocellular Carcinoma: A New Update

The Role of Hepatic Arterial Infusion Chemotherapy in the Treatment of Hepatocellular Carcinoma: A Systematic Review and Meta-Analysis

A Pilot Study of Hepatic Arterial Infusion of Chemotherapy for Patients with Advanced Hepatocellular Carcinoma Who Have Failed Anti‐angiogenic Therapy

Systemic Therapy for Hepatocellular Carcinoma: Chinese Consensus-Based Interdisciplinary Expert Statements

Hepatic Arterial Infusion of Chemotherapy As a Salvage Therapy for Patients with Advanced Hepatocellular Carcinoma

Advancing hepatocellular carcinoma treatment with hepatic arterial infusion chemotherapy

Hepatic arterial infusion chemotherapy versus transarterial chemoembolization for unresectable hepatocellular carcinoma: A systematic review with meta-analysis

Chinese Expert Consensus on the Combination of Targeted Therapy and Immunotherapy with Locoregional Therapy for Intermediate/Advanced Hepatocellular Carcinoma

First- and Second-Line Treatments for Patients with Advanced Hepatocellular Carcinoma in China: A Systematic Review

Efficacy of hepatic arterial infusion chemotherapy and its combination strategies for advanced hepatocellular carcinoma: A network meta-analysis

HAIC versus TACE for patients with unresectable hepatocellular carcinoma: A systematic review and meta-analysis

Hepatic arterial infusion chemotherapy with implantable arterial access port for advanced-stage hepatocellular carcinoma: a case report

Techniques and status of hepatic arterial infusion chemotherapy for primary hepatobiliary cancers

Hepatic arterial infusion chemotherapy with anti-angiogenesis agents and immune checkpoint inhibitors for unresectable hepatocellular carcinoma and meta-analysis

Current Status of Hepatic Arterial Infusion Chemotherapy

High-Risk Hepatocellular Carcinoma: Hepatic Arterial Infusion Chemotherapy versus Transarterial Chemoembolization

The worthy role of hepatic arterial infusion chemotherapy in combination with anti-programmed cell death protein 1 monoclonal antibody immunotherapy in advanced hepatocellular carcinoma

Chinese Expert Consensus on Immunotherapy for Hepatocellular Carcinoma (2021 Edition)